Clinical trials: Chronic Primary Immune Thrombocytopenia (ITP), open to volunteers
- Condition Chronic Primary Immune Thrombocytopenia (ITP)
- Status Open to volunteers
- Age group Children (under 18)
Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP).
- Conditions
- Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
- Trial name
- Advance Jr (NCT07194850)
- Testing
- Efgartigimod IV
- Where
- 26 sites in France, Germany and 8 more
- Volunteers
- 24 people
- Sponsor
- argenx
ITP - Immune Thrombocytopenia
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
It is a single-center, single-arm, open-labeled clinical trial to evaluate the efficacy and safety of CAR-T cells therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP).
- Trial name
- NCT06352281
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China